ImmuCell reports 12% sales increase in Q2 driven by strong domestic demand.
ImmuCell reported preliminary Q2 2026 sales of $7.2 million, a 11.5% increase from the prior year, with total first-half sales reaching $17.5 million. Strong domestic demand and robust product availability offset a challenging international comparison year-over-year.
View filing at SEC.gov →